๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Discounting and decision making in the economic evaluation of health-care technologies

โœ Scribed by Karl Claxton; Mike Paulden; Hugh Gravelle; Werner Brouwer; Anthony J. Culyer


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
150 KB
Volume
20
Category
Article
ISSN
1057-9230

No coin nor oath required. For personal study only.

โœฆ Synopsis


Discounting costs and health benefits in cost-effectiveness analysis has been the subject of recent debate -some authors suggesting a common rate for both and others suggesting a lower rate for health. We show how these views turn on key judgments of fact and value: on whether the social objective is to maximise discounted health outcomes or the present consumption value of health; on whether the budget for health care is fixed; on the expected growth in the cost-effectiveness threshold; and on the expected growth in the consumption value of health. We demonstrate that if the budget for health care is fixed and decisions are based on incremental cost effectiveness ratios (ICERs), discounting costs and health gains at the same rate is correct only if the threshold remains constant. Expecting growth in the consumption value of health does not itself justify differential rates but implies a lower rate for both. However, whether one believes that the objective should be the maximisation of the present value of health or the present consumption value of health, adopting the social time preference rate for consumption as the discount rate for costs and health gains is valid only under strong and implausible assumptions about values and facts. Copyright


๐Ÿ“œ SIMILAR VOLUMES


Whither trial-based economic evaluation
โœ Mark J. Sculpher; Karl Claxton; Mike Drummond; Chris McCabe ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 142 KB ๐Ÿ‘ 1 views

## Abstract The randomised controlled trial (RCT) has developed a central role in applied costโ€effectiveness studies in health care as the __vehicle__ for analysis. This paper considers the role of trialโ€based economic evaluation in this era of explicit decision making. It is argued that any framew

Economic evaluation and the postponement
โœ Pieter H. M. van Baal; Talitha L. Feenstra; Johan J. Polder; Rudolf T. Hoogenvee ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 156 KB ๐Ÿ‘ 1 views

The inclusion of medical costs in life years gained in economic evaluations of health care technologies has long been controversial. Arguments in favour of the inclusion of such costs are gaining support, which shifts the question from whether to how to include these costs. This paper elaborates on

Estimating production costs in the econo
โœ Carmen Herrero; Juan D. Moreno-Ternero ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 160 KB ๐Ÿ‘ 1 views

## Abstract We propose a method for calculating the production costs of an intervention in a manner that accounts for differences in productive โ€˜effort.โ€™ This method could be used within a costโ€effectiveness analysis framework in the evaluation of new medical technologies, pharmaceuticals, treatmen

Alternative decision modelling technique
โœ Jonathan Karnon ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 146 KB ๐Ÿ‘ 1 views

## Abstract Markov models have traditionally been used to evaluate the costโ€effectiveness of competing health care technologies that require the description of patient pathways over extended time horizons. Discrete event simulation (DES) is a more flexible, but more complicated decision modelling t